Comparative killing rates of fluoroquinolones and cell wall-active agents

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 5, 2000, Pages 1377-1380

  Fung Tomc, Joan C ^a   Gradelski, Elizabeth ^a   Valera, Lourdes ^a   Kolek, Benjamin ^a   Bonner, Daniel P ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFOTAXIME; CEFTRIAXONE; GATIFLOXACIN; LEVOFLOXACIN; METICILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN; VANCOMYCIN;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CELL VIABILITY; DRUG POTENCY; ENTEROBACTERIACEAE; ENTEROCOCCUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STREPTOCOCCUS;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; CELL WALL; ENTEROBACTERIACEAE; ENTEROCOCCUS FAECALIS; FLUOROQUINOLONES; LACTAMS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; TIME FACTORS; VANCOMYCIN;

EID: 0034102332     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.5.1377-1380.2000     Document Type: Article

References (15)

1. Boswell, F. J., J. M. Andrews, R. Wise, and A. Dalhoff. 1999. Bactericidal properties of moxifloxacin and post-antibiotic effect. J. Antimicrob. Chemother. 43(Suppl. B):43-49.
2. 14C]temafloxacin in cardiac vegetations. Antimicrob. Agents Chemother. 36:2216-2221.
3. Debbia, E., G. C. Schito, G. Nicoletti, and A. Speciale. 1987. In vitro activity of pefloxacin against gram-negative and gram-positive bacteria in comparison with other antibiotics. Chemioterapia 4:319-323.
4. Entenza, J. M., M. Blatter, M. P. Glauser, and P. Moreillon. 1994. Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci. Antimicrob. Agents Chemother. 38:2683-2688.
5. Entenza, J. M., J. Vouillamoz, M. P. Glauser, and P. Moreillon. 1999. Efficacy of trovafloxacin in treatment of experimental staphylococcal or streptococcal endocarditis. Antimicrob. Agents Chemother. 43:77-84.
6. Fung-Tomc, J. C., E. Gradelski, E. Huczko, T. J. Dougherty, R. E. Kessler, and D. P. Bonner. 1996. Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins. Antimicrob. Agents Chemother. 40:1289-1293.
7. Hoellman, D. B., G. Lin, M. R. Jacobs, and P. C. Appelbaum. 1999. Antipneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents. J. Antimicrob. Chemother. 43:645-649.
8. Johnson, C. C. 1996. In vitro testing: correlations of bacterial susceptibility, body fluid levels, and effectiveness of antibacterial therapy, p. 813-834. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co, Baltimore, Md.
9. Lewin, C. S. 1992. Antibacterial activity of a 1,8-naphthyridine quinolone, PD 131628. J. Med. Microbiol. 36:353-357.
10. Lewin, C. S., I. Morrissey, and J. T. Smith. 1991. The fluoroquinolones exert a reduced rate of kill against Enterococcus faecalis. J. Pharm. Pharmacol. 43: 492-494.
11. Morrissey, I. 1996. Bactericidal activity of trovafloxacin (CP-99,219). J. Antimicrob. Chemother. 38:1061-1066.
12. Morrissey, I. 1997. Bactericidal index: a new way to assess quinolone bactericidal activity in vitro. J. Antimicrob. Chemother. 39:713-717.
13. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS document no. M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
14. National Committee for Clinical Laboratory Standards. 1999. Methods for determining bactericidal activity of antimicrobial agents. NCCLS document no. M26-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
15. Schick, D. G., H. N. Canawati, and J. Z. Montgomerie. 1997. In vitro activity of the combination of trovafloxacin and other antibiotics against enterococci. Diagn. Microbiol. Infect. Dis. 29:233-239.